drugset / Trial / NCT02483312
A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)
Phase 1
Active not recruiting
9 enrolled
University Health Network, Toronto
Ozmosis Research Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant. This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.
Timeline
- Start
- 2015-09
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interleukin-12 | Protein / enzyme biologic | — | Intravenous |